Predictive and Prognostic Role of Systemic Immune-Inflammation Index (SII) in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
Mateusz Malik,
Barbara Radecka,
Marek Gełej,
Aleksandra Jackowska,
Emilia Filipczyk-Cisarż,
Michalina Żurowska,
Katarzyna Hetman,
Małgorzata Foszczyńska-Kłoda,
Beata Kania-Zembaczyńska,
Danuta Mańka,
Marlena Orlikowska,
Lubomir Bodnar
Affiliations
Mateusz Malik
Clinical Oncology Department, Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland
Barbara Radecka
Department of Oncology, Institute of Medical Sciences, University of Opole, 45-040 Opole, Poland
Marek Gełej
Department of Oncology, Institute of Medical Sciences, University of Opole, 45-040 Opole, Poland
Aleksandra Jackowska
Oncology and Immunooncology Clinic, Warmia and Mazury Oncology Centre, MSWiA Hospital, 10-228 Olsztyn, Poland
Emilia Filipczyk-Cisarż
Clinical Oncology Department, Lower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland
Michalina Żurowska
Department of Clinical Oncology and Radiotherapy, St. John Paul II Mazovia Regional Hospital in Siedlce, 08-110 Siedlce, Poland
Katarzyna Hetman
Department of Clinical Oncology, West Pomeranian Oncology Center in Szczecin, 71-730 Szczecin, Poland
Małgorzata Foszczyńska-Kłoda
Department of Clinical Oncology, West Pomeranian Oncology Center in Szczecin, 71-730 Szczecin, Poland
Beata Kania-Zembaczyńska
Department of Oncology and Oncohematology, Beskid Oncology Centre in Bielsko-Biala, 43-300 Bielsko Biala, Poland
Danuta Mańka
Department of Oncology and Oncohematology, Beskid Oncology Centre in Bielsko-Biala, 43-300 Bielsko Biala, Poland
Marlena Orlikowska
Oncology Department, Kociewie Health Centre, 83-200 Starogard Gdanski, Poland
Lubomir Bodnar
Department of Clinical Oncology and Radiotherapy, St. John Paul II Mazovia Regional Hospital in Siedlce, 08-110 Siedlce, Poland
In advanced-stage colorectal cancer (CRC), a strategy based on a sequence of systemic therapies brings survival benefits in most patients. Trifluridine and tipiracil hydrochloride (TT) is a chemotherapy drug effective in patients in the third- or later line setting. No highly specific biomarkers have been established for TT therapy so far. However, a systemic immune-inflammation index (SII), which is based on platelet, neutrophil and lymphocyte counts is applied to predict prognosis. In this retrospective, multicenter study, clinical data on 179 metastatic CRC patients treated with TT were collected. To evaluate factors predicting TT therapy response and overall survival, univariate logistic regression analysis was conducted. Subsequently, factors with p p = 0.0038), carcinoembryonic antigen (CEA) p = 0.0316) and SII ≤ 550 (p = 0.007). Favorable prognostic factors revealed in the multivariate analysis of overall survival (OS) were: p = 0.02), good to moderate histological differentiation (p = 0.0003), CEA p = 0.0227) and SII ≤ 550 (p = 0.0001). Our study indicated that pre-treatment SII may be clinically useful for selecting likely responder patients and assessing the prognosis for mCRC patients treated with TT.
